Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 156

1.

Chronic hepatitis B: what should be the goal for new therapies?

Block TM, Gish R, Guo H, Mehta A, Cuconati A, Thomas London W, Guo JT.

Antiviral Res. 2013 Apr;98(1):27-34. doi: 10.1016/j.antiviral.2013.01.006. Epub 2013 Feb 4.

2.

Treatment of chronic hepatitis B virus infection - Dutch national guidelines.

Buster EH, van Erpecum KJ, Schalm SW, Zaaijer HL, Brouwer JT, Gelderblom HC, de Knegt RJ, Minke Bakker C, Reesink HW, Janssen HL; Netherlands Association of Gastroenterologists and Hepatologists.

Neth J Med. 2008 Jul-Aug;66(7):292-306. Review.

3.

Management of viral hepatitis B.

Pramoolsinsup C.

J Gastroenterol Hepatol. 2002 Feb;17 Suppl:S125-45. Review.

PMID:
12000599
4.

Treatment of chronic hepatitis B: case selection and duration of therapy.

Leung N.

J Gastroenterol Hepatol. 2002 Apr;17(4):409-14. Review.

PMID:
11982721
5.

On-treatment monitoring of chronic hepatitis B virus infection: an Asian-Pacific perspective.

Chien RN.

J Gastroenterol Hepatol. 2010 May;25(5):852-7. doi: 10.1111/j.1440-1746.2010.06271.x. Review.

PMID:
20546437
6.

PegIFN-α2a for the treatment of chronic hepatitis B and C: a 10-year history.

Degasperi E, Viganò M, Aghemo A, Lampertico P, Colombo M.

Expert Rev Anti Infect Ther. 2013 May;11(5):459-74. doi: 10.1586/eri.13.37. Review.

PMID:
23627852
7.

A multi-center open study to determine the effect of lamivudine on HBV DNA clearance and to assess the safety of the regimen in patients with chronic hepatitis B infection.

Mazur W, Król F, Cianciara J, Nazzal K, Gładysz A, Juszczyk J, Bolewska B, Adamek J, Czajka B, Swietek K, Kryczka W, Gonciarz Z.

Med Sci Monit. 2002 Apr;8(4):CR257-62.

PMID:
11951067
8.

Molecular mechanisms of resistance to antiviral therapy in patients with chronic hepatitis B.

Yuan HJ, Lee WM.

Curr Mol Med. 2007 Mar;7(2):185-97. Review.

PMID:
17346170
9.

Therapy of viral hepatitis.

Hoofnagle JH.

Digestion. 1998 Aug;59(5):563-78. Review.

PMID:
9705540
10.

Chronic hepatitis B: Virology, natural history, current management and a glimpse at future opportunities.

Gish RG, Given BD, Lai CL, Locarnini SA, Lau JY, Lewis DL, Schluep T.

Antiviral Res. 2015 Sep;121:47-58. doi: 10.1016/j.antiviral.2015.06.008. Epub 2015 Jun 16. Review.

PMID:
26092643
11.

Restored function of HBV-specific T cells after long-term effective therapy with nucleos(t)ide analogues.

Boni C, Laccabue D, Lampertico P, Giuberti T, Viganò M, Schivazappa S, Alfieri A, Pesci M, Gaeta GB, Brancaccio G, Colombo M, Missale G, Ferrari C.

Gastroenterology. 2012 Oct;143(4):963-73.e9. doi: 10.1053/j.gastro.2012.07.014. Epub 2012 Jul 14.

PMID:
22796241
12.

Prevention of hepatocellular carcinoma in hepatitis B virus infection.

Lim SG, Mohammed R, Yuen MF, Kao JH.

J Gastroenterol Hepatol. 2009 Aug;24(8):1352-7. doi: 10.1111/j.1440-1746.2009.05985.x. Review.

PMID:
19702903
13.

Emerging pipeline drugs for hepatitis B infection.

Cox N, Tillmann H.

Expert Opin Emerg Drugs. 2011 Dec;16(4):713-29. doi: 10.1517/14728214.2011.646260. Review.

PMID:
22195605
14.

[Clinical characteristics and effect of secondary individualized therapy in chronic hepatitis B patients infected with the rtA181 mutation hepatitis B virus].

Ji FZ, Wang L, Yang BH, Zhao JJ, Liu F, Xue Y, Li T.

Zhonghua Gan Zang Bing Za Zhi. 2012 Apr;20(4):280-4. doi: 10.3760/cma.j.issn.1007-3418.2012.04.011. Chinese.

PMID:
22964149
15.

Chronic hepatitis B: early viral suppression and long-term outcomes of therapy with oral nucleos(t)ides.

Nguyen MH, Keeffe EB.

J Viral Hepat. 2009 Mar;16(3):149-55. doi: 10.1111/j.1365-2893.2009.01078.x. Review.

PMID:
19236641
16.

Antiviral therapy for chronic hepatitis B.

Jafri SM, Lok AS.

Clin Liver Dis. 2010 Aug;14(3):425-38. doi: 10.1016/j.cld.2010.05.005. Review.

PMID:
20638023
17.

Chronic hepatitis B: who to treat and which choice of treatment?

Di Marco V, Craxì A.

Expert Rev Anti Infect Ther. 2009 Apr;7(3):281-91. doi: 10.1586/eri.09.4. Review.

PMID:
19344242
18.

Treatment of HBeAg positive chronic hepatitis B: interferon or nucleoside analogues.

Dusheiko G.

Liver Int. 2013 Feb;33 Suppl 1:137-50. doi: 10.1111/liv.12078. Review.

PMID:
23286858
19.

Impact of viral replication inhibition by entecavir on peripheral T lymphocyte subpopulations in chronic hepatitis B patients.

You J, Sriplung H, Geater A, Chongsuvivatwong V, Zhuang L, Li YL, Lei H, Liu J, Chen HY, Tang BZ, Huang JH.

BMC Infect Dis. 2008 Sep 22;8:123. doi: 10.1186/1471-2334-8-123.

20.

Impact of therapy on the outcome of chronic hepatitis B.

Liaw YF.

Liver Int. 2013 Feb;33 Suppl 1:111-5. doi: 10.1111/liv.12057. Review.

PMID:
23286854
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk